Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | EIF4E | P06730 | 7/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | RARG | P13631 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPA | Q15257 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902748 | 0.94 | LMNA (0.48) | LMNAEIF4ERARARARBRARG | |
| SCHEMBL4905616 | 0.92 | LMNA (0.46) | LMNAEIF4ERARARARBRARG | |
| SCHEMBL4902506 | 0.91 | LMNA (0.43) | LMNAALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL4905782 | 0.91 | ALDH1A1 (0.44) | LMNAALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL4908424 | 0.90 | LMNA (0.42) | LMNAEIF4ERARARARBRARG | |
| SCHEMBL4906947 | 0.90 | LMNA (0.46) | LMNAEIF4ERARARARBRARG | |
| SCHEMBL4904293 | 0.89 | LMNA (0.45) | LMNARARARARBRARGALDH1A1 | |
| SCHEMBL4901463 | 0.87 | ALDH1A1 (0.44) | LMNARARARARBRARGALDH1A1 | |
| SCHEMBL4906041 | 0.86 | ALDH1A1 (0.52) | LMNAALDH1A1PTPRCPTPN2PTPN1 | |
| SCHEMBL4904348 | 0.86 | LMNA (0.47) | LMNARARARARBRARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | LMNA 319/4885EIF4E 3036/4885RARA 431/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | LMNA 319/4885EIF4E 3036/4885RARA 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.